- Home
- MBBC vs QTTB Comparison
MBBC vs QTTB Comparison
Compare MBBC & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBBC
- QTTB
- Stock Information
- Founded
- MBBC 1902
- QTTB 2015
- Country
- MBBC United States
- QTTB United States
- Employees
- MBBC N/A
- QTTB N/A
- Industry
- MBBC Banks
- QTTB Biotechnology: Pharmaceutical Preparations
- Sector
- MBBC Finance
- QTTB Health Care
- Exchange
- MBBC Nasdaq
- QTTB Nasdaq
- Market Cap
- MBBC 22.1M
- QTTB 19.0M
- IPO Year
- MBBC N/A
- QTTB N/A
- Fundamental
- Price
- MBBC $10.04
- QTTB $1.55
- Analyst Decision
- MBBC
- QTTB Hold
- Analyst Count
- MBBC 0
- QTTB 8
- Target Price
- MBBC N/A
- QTTB $24.00
- AVG Volume (30 Days)
- MBBC 9.6K
- QTTB 108.7K
- Earning Date
- MBBC 05-14-2025
- QTTB 08-07-2025
- Dividend Yield
- MBBC N/A
- QTTB N/A
- EPS Growth
- MBBC 103.56
- QTTB N/A
- EPS
- MBBC 0.22
- QTTB N/A
- Revenue
- MBBC $6,591,743.00
- QTTB N/A
- Revenue This Year
- MBBC N/A
- QTTB N/A
- Revenue Next Year
- MBBC N/A
- QTTB N/A
- P/E Ratio
- MBBC $45.59
- QTTB N/A
- Revenue Growth
- MBBC N/A
- QTTB N/A
- 52 Week Low
- MBBC $6.05
- QTTB $1.38
- 52 Week High
- MBBC $12.00
- QTTB $53.79
- Technical
- Relative Strength Index (RSI)
- MBBC N/A
- QTTB 39.02
- Support Level
- MBBC N/A
- QTTB $1.63
- Resistance Level
- MBBC N/A
- QTTB $1.85
- Average True Range (ATR)
- MBBC 0.00
- QTTB 0.13
- MACD
- MBBC 0.00
- QTTB -0.03
- Stochastic Oscillator
- MBBC 0.00
- QTTB 7.92
About QTTB Q32 Bio Inc. Common Stock
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.